Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2immunotherapy and isotretinoin: a prospective Phase II study-Reference-Cited by-同舟云学术

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2immunotherapy and isotretinoin: a prospective Phase II study

Published:2015-05-22 Issue:7 Volume:4 Page:e1016704
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Kushner Brian H,Ostrovnaya Irina,Cheung Irene Y,Kuk Deborah,Kramer Kim,Modak Shakeel,Yataghene Karima,Cheung Nai-Kong V

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.1080/2162402X.2015.1016704

Reference48 articles.

1. New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome: Figure 1.

2. Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid

3. Disseminated Neuroblastoma in Children Older Than One Year at Diagnosis: Comparable Results With Three Consecutive High-Dose Protocols Adopted by the Italian Co-Operative Group for Neuroblastoma

4. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial

5. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ONC201 Exerts Oncogenic Effects Beyond its Mitochondria-Disturbing Role in Neuroblastoma Subsets;2024-07-19

2. Intraoperative Radiation Therapy for Relapsed or Refractory High-Risk Neuroblastoma: A 27-Year Experience;Practical Radiation Oncology;2024-05

3. Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells;Journal for ImmunoTherapy of Cancer;2024-03

4. Re-Engaging the Immune System: Immunotherapy for Neuroblastoma;Pediatric Oncology;2024

5. Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells;2023-11-09